Jinyu Bio-technology Balance Sheet Health
Financial Health criteria checks 6/6
Jinyu Bio-technology has a total shareholder equity of CN¥5.5B and total debt of CN¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CN¥6.9B and CN¥1.4B respectively. Jinyu Bio-technology's EBIT is CN¥107.6M making its interest coverage ratio -2. It has cash and short-term investments of CN¥1.3B.
Key information
0%
Debt to equity ratio
CN¥0
Debt
| Interest coverage ratio | -2x |
| Cash | CN¥1.31b |
| Equity | CN¥5.55b |
| Total liabilities | CN¥1.35b |
| Total assets | CN¥6.90b |
Recent financial health updates
No updates
Recent updates
The Consensus EPS Estimates For Jinyu Bio-technology Co., Ltd. (SHSE:600201) Just Fell Dramatically
Sep 04
Revenue Miss: Jinyu Bio-technology Co., Ltd. Fell 9.1% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models
Sep 02Why We're Not Concerned Yet About Jinyu Bio-technology Co., Ltd.'s (SHSE:600201) 25% Share Price Plunge
Jun 16Jinyu Bio-technology Co., Ltd. (SHSE:600201) Analysts Are Reducing Their Forecasts For This Year
Apr 30There's Reason For Concern Over Jinyu Bio-technology Co., Ltd.'s (SHSE:600201) Price
Mar 21Does This Valuation Of Jinyu Bio-technology Co., Ltd. (SHSE:600201) Imply Investors Are Overpaying?
Feb 28Financial Position Analysis
Short Term Liabilities: 600201's short term assets (CN¥2.4B) exceed its short term liabilities (CN¥693.7M).
Long Term Liabilities: 600201's short term assets (CN¥2.4B) exceed its long term liabilities (CN¥660.3M).
Debt to Equity History and Analysis
Debt Level: 600201 is debt free.
Reducing Debt: 600201 has no debt compared to 5 years ago when its debt to equity ratio was 1.1%.
Debt Coverage: 600201 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 600201 has no debt, therefore coverage of interest payments is not a concern.